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BACKGROUND
The effects of less-tight versus tight control of hypertension on pregnancy compli-
cations are unclear.
METHODS
We performed an open, international, multicenter trial involving women at 14 weeks 
0 days to 33 weeks 6 days of gestation who had nonproteinuric preexisting or ges-
tational hypertension, office diastolic blood pressure of 90 to 105 mm Hg (or 85 to 
105 mm Hg if the woman was taking antihypertensive medications), and a live fetus. 
Women were randomly assigned to less-tight control (target diastolic blood pres-
sure, 100 mm Hg) or tight control (target diastolic blood pressure, 85 mm Hg). The 
composite primary outcome was pregnancy loss or high-level neonatal care for more 
than 48 hours during the first 28 postnatal days. The secondary outcome was seri-
ous maternal complications occurring up to 6 weeks post partum or until hospital 
discharge, whichever was later.
RESULTS
Included in the analysis were 987 women; 74.6% had preexisting hypertension. The 
primary-outcome rates were similar among 493 women assigned to less-tight con-
trol and 488 women assigned to tight control (31.4% and 30.7%, respectively; ad-
justed odds ratio, 1.02; 95% confidence interval [CI], 0.77 to 1.35), as were the rates 
of serious maternal complications (3.7% and 2.0%, respectively; adjusted odds ratio, 
1.74; 95% CI, 0.79 to 3.84), despite a mean diastolic blood pressure that was higher 
in the less-tight-control group by 4.6 mm Hg (95% CI, 3.7 to 5.4). Severe hyperten-
sion (≥160/110 mm Hg) developed in 40.6% of the women in the less-tight-control 
group and 27.5% of the women in the tight-control group (P<0.001).
CONCLUSIONS
We found no significant between-group differences in the risk of pregnancy loss, 
high-level neonatal care, or overall maternal complications, although less-tight con-
trol was associated with a significantly higher frequency of severe maternal hyper-
tension. (Funded by the Canadian Institutes of Health Research; CHIPS Current Con-
trolled Trials number, ISRCTN71416914; ClinicalTrials.gov number, NCT01192412.)
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Almost 10% of pregnant women have hypertension; hypertension is preexisting in 1%, gestational hypertension without 
proteinuria develops in 5 to 6%, and preeclamp-
sia develops in 2%.1 Preexisting hypertension 
and gestational hypertension before 34 weeks 
are associated with an increased risk of perinatal 
and maternal complications.2-4
Blood-pressure targets for women with non-
severe hypertension during pregnancy are much 
debated. Relevant randomized, controlled trials 
have been small and of moderate or poor quality; 
tight control (the use of antihypertensive therapy 
to normalize blood pressure) has been associated 
with maternal benefits (e.g., a decrease in the fre-
quency of severe hypertension and possibly in the 
rate of antenatal hospitalization)5,6 but sometimes, 
though not consistently, with perinatal risks 
(e.g., poor fetal growth and well-being).7-9
International guidelines for nonsevere hyper-
tension during pregnancy recommend treatment 
goals consistent with either less-tight control 
(blood pressure that is higher than normal but 
not severely elevated) or tight control.10-13 The Con-
trol of Hypertension in Pregnancy Study (CHIPS) 
was designed to compare less-tight control with 
tight control of nonproteinuric, nonsevere hyper-
tension in pregnancy with respect to perinatal 
and maternal outcomes.
Me thods
Study Design and Oversight
CHIPS was an open, multicenter, international, 
randomized, controlled trial. The study was ap-
proved by the research ethics board at the Univer-
sity of British Columbia (the coordinating center) 
and at all study sites, and the protocol is available 
with the full text of this article at NEJM.org. There 
was no commercial sponsorship. The fifth and 
15th authors assume responsibility for the ac-
curacy and completeness of data reporting, and 
the first and ninth authors vouch for the fidelity 
of the analyses to the protocol. All study par-
ticipants provided written, informed consent.
Women were included if they had nonsevere, 
nonproteinuric preexisting hypertension or ges-
tational hypertension; a diastolic blood pressure 
of 90 to 105 mm Hg if they were not receiving 
antihypertensive therapy, or 85 to 105 mm Hg if 
they were receiving such treatment; and a live sin-
gleton fetus at 14 weeks 0 days to 33 weeks 6 days 
of gestation (determined in most cases by early 
pregnancy ultrasound examination). Preexisting 
hypertension was defined as diastolic blood pres-
sure of 90 mm Hg or higher before pregnancy or 
before 20 weeks 0 days of gestation. Gestational 
hypertension was defined as diastolic blood pres-
sure of 90 mm Hg or higher at 20 weeks or more 
of gestation.14 Korotkoff phase V was used to de-
termine diastolic blood pressure. Blood-pressure 
measurements were obtained by a health care 
professional at least 4 hours apart or at two con-
secutive outpatient visits, with the second measure-
ment taken within 1 week before randomization. 
The values of both measurements were required 
to be elevated.
Women were excluded if they had a systolic 
blood pressure of 160 mm Hg or higher (although 
they could be included subsequently if the sys-
tolic blood pressure was reduced to <160 mm Hg 
with treatment and they met all other eligibility 
criteria),14,15 had proteinuria (i.e., ≥0.3 g of protein 
in a 24-hour urine collection, a urinary protein: 
creatinine ratio of ≥263 [with protein measured in 
milligrams per day and creatinine in grams per 
day], or a urinary dipstick result of ≥2+),14 used 
an angiotensin-converting–enzyme (ACE) inhibi-
tor at 14 weeks 0 days of gestation or later, had a 
contraindication to either trial group because of a 
preexisting condition (e.g., pregestational diabe-
tes or renal disease) or needed to be delivered for 
maternal or fetal reasons, had a known multiple 
gestation or a fetus with a major anomaly or chro-
mosomal abnormality, had plans to terminate 
the pregnancy, or had previously participated in 
CHIPS.
Randomization, which was stratified accord-
ing to center and type of hypertension (preexist-
ing or gestational), was performed in permuted 
blocks of random size (2 or 4) by site coordina-
tors at a central site, with the use of a toll-free 
telephone line (Centre for Mother, Infant, and 
Child Research, University of Toronto) that was 
accessible 24 hours a day and backed up by a 
pager system. The assignment sequence was gen-
erated by a programmer who used SAS software, 
version 9.2 (SAS Institute); the sequences were 
secured and available only to the system manager, 
and the telephone line was password protected.
Eligible women were randomly assigned in a 1:1 
ratio to less-tight control (target diastolic blood 
pressure, 100 mm Hg) (Fig. S1A in the Supplemen-
tary Appendix, available at NEJM.org) or tight 
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control (target diastolic blood pressure, 85 mm Hg) 
(Fig. S1B in the Supplementary Appendix) until 
delivery, with the goal of a between-group dif-
ference in diastolic blood pressure of 5 mm Hg, 
a difference that was similar to that achieved in 
our pilot trial.9 We anticipated that the average 
diastolic blood pressure in the less-tight-control 
group would be below 100 mm Hg and that the 
between-group difference in diastolic blood pres-
sure would be less than 15 mm Hg, because most 
women who have hypertension without coexist-
ing conditions have mild hypertension and would 
remain off antihypertensive medication after ran-
domization. The study protocol recommended 
labetalol as the drug of first choice. ACE inhibi-
tors, angiotensin-receptor antagonists, direct re-
nin inhibitors, and atenolol were not permitted 
before delivery.14,16 No antihypertensive drugs were 
provided by the study.
Standardized measurement of blood pressure 
was performed in outpatient settings by health 
professionals who obtained three blood-pressure 
measurements. The average of the second and 
third diastolic blood-pressure measurements was 
considered to be the diastolic blood pressure for 
that visit17; this information was recorded in a 
patient-held diary, where potential cointerventions 
(e.g., clinic visits and fetal ultrasound examina-
tions) were also recorded.
Women were seen by their maternity care pro-
vider within 4 weeks after randomization, at 
which time adherence to the recommended algo-
rithm (i.e., actions taken to achieve a target dia-
stolic blood pressure of 100 to 104 mm Hg or 81 
to 85 mm Hg) (Fig. S1 in the Supplementary 
Appendix) and “clinically reasonable” adherence 
(i.e., actions taken to achieve a diastolic blood 
pressure 5 mm Hg above or below the target 
value of 100 mm Hg or 85 mm Hg) were evalu-
ated (Table S2 in the Supplementary Appendix). 
Thereafter, women were seen according to a sched-
ule determined by their maternity care provider. 
Data on blood-pressure measurements and coin-
terventions were collected from the patients’ dia-
ries during meetings (in person or by phone) 
with the site coordinator (at 14 to 20, 21 to 28, 
29 to 33, and 34 to 40 weeks of gestation and at 
delivery). Outcome data were obtained from ma-
ternal and infant charts. At or after 6 weeks post 
partum and when the baby was at least 36 weeks 
of corrected postgestational age, a standardized 
maternal questionnaire was administered once 
(in person or by phone) by site coordinators to 
identify postdischarge maternal or neonatal com-
plications.
Study Outcomes
The primary outcome was a composite of preg-
nancy loss (defined as miscarriage, ectopic preg-
nancy, pregnancy termination, stillbirth, or neo-
natal death) or high-level neonatal care (defined 
as greater-than-normal newborn care) for more 
than 48 hours until 28 days of life or until dis-
charge home, whichever was later. The second-
ary outcome was serious maternal complications 
occurring up to 6 weeks post partum or until 
hospital discharge, whichever was later. Serious 
maternal complications included death, stroke, 
eclampsia, blindness, uncontrolled hypertension, 
the use of inotropic agents, pulmonary edema, 
respiratory failure, myocardial ischemia or infarc-
tion, hepatic dysfunction, hepatic hematoma or 
rupture, renal failure, and transfusion18 (see Ta-
ble S3 in the Supplementary Appendix for all defi-
nitions). The primary and secondary outcomes 
were adjudicated centrally by an expert commit-
tee whose members were unaware of the group 
assignments and were not involved in the care of 
patients in the cases under review. Other outcomes 
included components of the primary and second-
ary outcomes, measures of fetal growth and 
newborn complications, and severe hypertension 
(≥160/110 mm Hg) in the mother.
Statistical Analysis
We estimated that with a sample size of 514 per 
group, the study would have 80% power, at a 
two-tailed alpha level of 0.05, assuming primary 
outcome rates of 33% in the tight-control group 
and 25% in the less-tight-control group, a 10% 
rate of crossover, a 1% loss to follow-up, and 
two interim analyses,9 as calculated with the chi-
square test with the use of East software (Cytel) 
and the Lan–DeMets spending function with 
O’Brien–Fleming–type boundaries for early stop-
ping. Analyses were performed according to the 
intention-to-treat principle. The unit of analysis 
was the individual woman.
The primary outcome and all dichotomous 
outcomes were analyzed with the use of a mixed-
effects logistic-regression model, with adjustment 
for the stratification factors, the use of any anti-
hypertensive therapy at the time of randomiza-
tion, prerandomization blood pressure of 160/110 
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mm Hg or higher during this pregnancy, gesta-
tional diabetes, and any factor with apparent 
dissimilarity between the groups at baseline.19 
The alpha level was set at 0.046 for the primary 
outcome, on the basis of the Lan–DeMets spend-
ing function with O’Brien–Fleming–type bound-
aries and two interim analyses (with P<0.0002 
and P<0.012 used as guidelines by the data and 
safety monitoring board at the Centre for Mother, 
Infant, and Child Research for the consideration 
of early termination of the trial at the first and 
second interim analyses, respectively). To accom-
modate the many comparisons made, two-tailed 
P values of less than 0.01 for the secondary out-
comes and less than 0.001 for other outcomes 
were considered to indicate statistical significance. 
Exploratory analyses of the primary and second-
ary outcomes, birth weight less than the 10th 
percentile,20 severe hypertension, and preeclamp-
sia included interactions between treatment and 
five prognostic factors from the adjusted logistic-
regression model, the perinatal mortality ratio of 
the recruiting country, and clinically reasonable 
adherence; for these exploratory analyses, the 
Breslow–Day test of homogeneity was used and 
P values of less than 0.05 were considered to 
indicate statistical significance.
Blood-pressure measurements after random-
ization were compared between groups with the 
use of a mixed-effects logistic-regression model, 
which accounted for participants having different 
numbers of observations over a varying time span. 
The patient was a random effect, and treatment 
group and time point were fixed effects.
R esult s
Enrollment and Randomization
Among 111 active sites, 95 sites in 16 countries 
enrolled at least one woman (1030 recruits from 
March 26, 2009, to August 2, 2012). A total of 
519 women were randomly assigned to less-tight 
control and 511 to tight control of diastolic blood 
pressure. One site (in which 43 women were en-
rolled) was excluded before the analyses on the 
advice of the CHIPS steering committee and the 
data and safety monitoring board owing to con-
cerns about informed consent and data integrity. 
At the remaining 94 sites, the median number of 
annual deliveries was 3700 (interquartile range, 
2650 to 5000). A total of 45 sites (47.9%) reported 
detailed information on the 881 women at their 
sites who were identified as eligible, of whom 496 
(56.3%) enrolled and 385 (43.7%) declined en-
rollment (for the reasons for nonparticipation, 
see Table S4 in the Supplementary Appendix).
After exclusion of the women from one site, 
497 women were randomly assigned to less-tight 
control and 490 to tight control (Fig. 1). Subse-
quently, 3 women withdrew from the study and 
3 women were lost to follow-up before delivery; 
we have no primary or secondary outcome data for 
these women (Fig. 1). Thirteen women assigned to 
less-tight control and 11 women assigned to 
tight control were reported to have discontinued 
their assigned blood-pressure treatment before 
delivery; they were included in the analyses accord-
ing to their assigned group. Five women in each 
group were lost to follow-up for the postpartum 
questionnaire. After enrollment, 8 women in the 
less-tight-control group and 13 in the tight-con-
trol group were found to have been ineligible, but 
they all remained in the study (Table S5 in the 
Supplementary Appendix).
The characteristics of participants at trial 
entry are shown in Table 1 and in Table S5 in the 
Supplementary Appendix. The baseline charac-
teristics of the women were generally similar in 
the two groups; the number of weeks of gestation 
at enrollment appeared to be slightly greater in 
the group assigned to less-tight control than in the 
group assigned to tight control (prompting the 
inclusion of weeks of gestation in the adjusted 
logistic-regression model for all outcomes).
Postrandomization Blood Pressure, 
Adherence, and Cointerventions
The frequency of adherence to the recommended 
algorithm for management was similar in the less-
tight-control group and the tight-control group 
(74.1% and 73.4%, respectively; P = 0.81), but the 
frequency of clinically reasonable adherence was 
slightly lower in the less-tight-control group (76.6% 
vs. 82.0%, P = 0.04). Adherence could not be as-
sessed for 25 women (10 in the less-tight-control 
group and 15 in the tight-control group) who did 
not have an office visit or a clinic visit after ran-
domization. Few women (2 in the less-tight-con-
trol group and 1 in the tight-control group) had 
their medication adjusted for reasons other than 
blood-pressure control.
From randomization until delivery, blood pres-
sure was higher among women in the less-tight-
control group than among those in the tight-con-
n engl j med 372;5 nejm.org January 29, 2015 411
Control of Hypertension in Pregnancy
trol group, by a mean of 5.8 mm Hg systolic (95% 
confidence interval [CI], 4.5 to 7.0; 138.8±0.5 
mm Hg vs. 133.1±0.5 mm Hg, P<0.001) and 4.6 
mm Hg diastolic (95% CI, 3.7 to 5.4; 89.9±0.3 
mm Hg vs. 85.3±0.3 mm Hg, P<0.001).
Antihypertensive medication was taken after 
randomization by fewer women in the less-tight-
control group than in the tight-control group 
before delivery (73.4% vs. 92.6%, P<0.001) and 
after delivery (65.5% vs. 78.3%, P<0.001) (Table S6 
in the Supplementary Appendix). Among women 
receiving antihypertensive therapy, labetalol was 
the most commonly used agent overall (68.9% and 
68.8% in the two groups, respectively). There were 
four protocol violations (four women at different 
sites) involving postrandomization, predelivery 
use of atenolol. Otherwise, women in the less-
tight-control and tight-control groups received 
similar treatment (Table S6 in the Supplemen-
tary Appendix).
Figure 1. Enrollment and Randomization.
Data from 45 sites (881 women) indicated that 385 eligible women (43.7%) did not undergo randomization. A total 
of 16 additional centers were active but did not recruit any women into the study; these centers were in Brazil  
(3 centers), Canada (1 center), the Netherlands (4 centers), the United Kingdom (7 centers), and the United States 
(1 center). There was one active center (with no recruits) in Equatorial Guinea that was deactivated when the site in‑
vestigator moved. One site (which had enrolled 43 women) was excluded owing to concern about informed consent 
and data integrity.
1030 Patients underwent randomization
519 Women (519 fetuses) were assigned
to less-tight control
511 Women (511 fetuses) were assigned
to tight control
22 Were excluded 21 Were excluded
1 Woman was lost to 
follow-up
493 Women were included in the
secondary-outcome analysis
488 Women were included in the
secondary-outcome analysis
497 Women (497 fetuses) were included
in the analysis
490 Women (490 fetuses) were included
in the analysis
2 Women withdrew after
initial participation
2 Women were lost to 
follow-up
493 Fetuses or neonates were included
in the primary-outcome analysis
488 Fetuses or neonates were included
in the primary-outcome analysis
1 Withdrew before receiving
intervention and did not
consent to use of 
outcome data
497 Women (497 fetuses) underwent
less-tight control
489 Women (489 fetuses) underwent
tight control
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Outcomes
The median duration of study participation be-
fore delivery was 12.1 weeks (interquartile range, 
6.4 to 18.8) in the less-tight-control group and 
11.4 weeks (interquartile range, 6.6 to 19.0) in 
the tight-control group (P = 0.75). The gestational 
age at delivery and the frequency of cesarean 
delivery did not differ significantly between the 
groups (Table S7 in the Supplementary Appendix). 
Spontaneous vaginal delivery was more common 
in the less-tight-control group, but the P value of 
0.03 did not meet the prespecified level of sig-
nificance (P<0.001) for the “other outcomes” 
category.
The frequency of the primary outcome — 
pregnancy loss or high-level neonatal care for 
more than 48 hours — did not differ signifi-
cantly between the groups (Table 2, and Table S8 
in the Supplementary Appendix). Most perinatal 
deaths were stillbirths. Most high-level neonatal 
care for more than 48 hours was related to com-
plications of prematurity. There were no signifi-
cant between-group differences with respect to 
other perinatal outcomes, including the propor-
tion of newborns who were small for gestational 
age and the frequency of respiratory complica-
tions and treatment.
The frequency of the secondary outcome — 
serious complications (including death) — was 
also similar in the two groups (Table 3, and 
Table S9 in the Supplementary Appendix); given 
the low event rate, adjustment could be made 
only for hypertension type (preexisting vs. gesta-
tional) and previous severe hypertension. There 
were no maternal deaths. The most common ma-
ternal complication was the receipt of blood prod-
ucts. The frequency of abruption did not differ 
significantly between the groups. Most serious 
maternal complications occurred among women 
with preeclampsia (15 of 18 women in the less-
tight-control group and 6 of 10 in the tight-con-
trol group). The frequency of severe hypertension 
Characteristic
Less-Tight Control 
(N = 497)
Tight Control 
(N = 490)
Maternal age at expected date of delivery — yr 34.0±5.7 33.7±5.8
Body‑mass index — no./total no. (%)†
<18.5 1/493 (0.2) 2/485 (0.4)
18.5–24.9 116/493 (23.5) 112/485 (23.1)
25.0–29.9 131/493 (26.6) 135/485 (27.8)
≥30.0 245/493 (49.7) 236/485 (48.7)
Cigarette smoking during this pregnancy — no. (%) 35 (7.0) 28 (5.7)
Nulliparous — no. (%) 161 (32.4) 168 (34.3)
Weeks of gestation 23.7±6.3 24.2±6.3
Type of nonproteinuric hypertension — no. (%)
Preexisting hypertension 371 (74.6) 365 (74.5)
Gestational hypertension 126 (25.4) 125 (25.5)
Prior blood pressure ≥160 mm Hg systolic or ≥110 mm Hg diastolic 
during this pregnancy — no. (%)
82 (16.5) 59 (12.0)
Antihypertensive medication at enrollment — no. (%) 279 (56.1) 287 (58.6)
Blood pressure within 1 wk before randomization — mm Hg
Systolic 140.4±9.7 139.7±9.8
Diastolic 92.6±4.8 92.2±5.2
Currently monitoring blood pressure at home — no. (%) 185 (37.2) 194 (39.6)
Gestational diabetes at enrollment — no. (%) 32 (6.4) 31 (6.3)
*  Plus–minus values are means ±SD. There were no significant differences between the groups except with respect to pri‑
or blood pressure of 160 mm Hg or higher systolic or 110 mm Hg or higher diastolic during this pregnancy (P = 0.049).
†  Body‑mass index is the weight in kilograms divided by the square of the height in meters.
Table 1. Baseline Characteristics at Enrollment.*
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was higher among women in the less-tight-con-
trol group than among those in the tight-control 
group (P<0.001) (Fig. 2, Table 3, and Table S9 in 
the Supplementary Appendix); however, the dis-
tribution of observed systolic and diastolic blood-
pressure values (P = 0.63 and P = 0.72, respectively) 
was similar between the two groups, illustrating 
that the excess risk of severe hypertension among 
women in the less-tight-control group was not 
restricted to values just above the threshold. The 
frequency of a platelet count less than 100×109 per 
liter or an elevated liver-enzyme level with associ-
Variable
Less-Tight 
Control 
(N = 493)
Tight 
Control 
(N = 488)
Adjusted Odds 
Ratio  
(95% CI)†
Primary outcome — no. (%) 155 (31.4) 150 (30.7) 1.02 (0.77–1.35)
Pregnancy loss — no. (%) 15 (3.0) 13 (2.7) 1.14 (0.53–2.45)
Miscarriage 0 1 (0.2)
Ectopic pregnancy 0 0
Elective termination‡ 1 (0.2) 1 (0.2)
Perinatal death 14 (2.8) 11 (2.3) 1.25 (0.56–2.81)
Stillbirth 12 (2.4) 7 (1.4)
Neonatal death 2 (0.4) 4 (0.8)
High‑level neonatal care for >48 hr — no./total no. 
(%)§
141/480 (29.4) 139/479 (29.0) 1.00 (0.75–1.33)
Gestational age at delivery — wk 36.8±3.4 37.2±3.1
Small‑for‑gestational‑age newborns — no./total no. 
(%)¶
Birth weight <10th percentile 79/491 (16.1) 96/488 (19.7) 0.78 (0.56–1.08)
Birth weight <3rd percentile 23/491 (4.7) 26/488 (5.3) 0.92 (0.51–1.63)
Other perinatal outcomes of liveborn infants
Respiratory complications — no./total no. (%)
Clinical respiratory problem 82/480 (17.1) 67/479 (14.0) 1.19 (0.83–1.71)
Administration of oxygen beyond the first 10 
min of life
34/479 (7.1) 25/477 (5.2) 1.24 (0.72–2.14)
Ventilatory support (with or without intuba‑
tion) beyond the first 10 min of life
35/478 (7.3) 38/479 (7.9) 0.86 (0.53–1.40)
Use of surfactant 28/480 (5.8) 26/479 (5.4) 0.97 (0.55–1.69)
At least one serious neonatal complication — 
no./total no. (%)‖
40/480 (8.3) 40/479 (8.4) 0.96 (0.60–1.52)
*  Plus–minus values are means ±SD. The primary outcome was a composite of pregnancy loss or high‑level neonatal 
care for more than 48 hours. There were no significant differences between the groups.
†  The mixed‑effects logistic‑regression model was adjusted for stratification factors (type of hypertension [preexisting vs. 
gestational] and center), the use of any antihypertensive therapy at randomization, previous blood pressure of 160/110 
mm Hg or higher during this pregnancy, gestational diabetes, and weeks of gestation at randomization.
‡  The reasons specified for elective termination were severe preeclampsia (one patient in the less‑tight‑control group, 
previability at 22 weeks 0 days of gestation) and fetal anomaly (one patient in the tight‑control group, at 23 weeks 4 
days of gestation).
§  Among liveborn infants admitted for high‑level neonatal care for more than 48 hours, four infants died (one born to a 
mother in the less‑tight‑control group and three born to mothers in the tight‑control group).
¶  Birth‑weight percentiles were determined for gestational age (22 to 43 weeks) and sex.17 Two babies were born after 22 
weeks of gestation (both to mothers in the less‑tight‑control group), with birth weights of 180 g and 426 g; they were 
excluded from the analysis.
‖  Serious neonatal complications were severe respiratory distress, sepsis in the first 48 hours of life, bronchopulmonary 
dysplasia, severe retinopathy of prematurity, central nervous system complications, and necrotizing enterocolitis (see 
Table S3 in the Supplementary Appendix for definitions).
Table 2. Primary and Other Perinatal Outcomes.*
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ated symptoms was higher among women in the 
less-tight-control group than among those in the 
tight-control group (P<0.05 for each comparison) 
but the difference did not meet the criterion for 
significance (i.e., P<0.001). Results for the primary 
and secondary outcomes were similar regardless 
of the type of hypertension, whether antihyperten-
sive therapy was being used at randomization, 
whether the mother had gestational diabetes, the 
perinatal mortality ratio of the recruiting coun-
try (Fig. S3 and Table S10 in the Supplementary 
Appendix), and whether there was clinically rea-
Variable
Less-Tight 
Control 
(N = 493)
Tight 
Control 
(N = 488)
Adjusted Odds Ratio 
(95% CI)†
Serious maternal complications — no. (%)‡ 18 (3.7) 10 (2.0) 1.74 (0.79–3.84)
Uncontrolled hypertension 0 0
Transient ischemic attack or stroke 0 1 (0.2)
Pulmonary edema 2 (0.4) 1 (0.2)
Renal failure 0 1 (0.2)
Transfusion§ 16 (3.2) 8 (1.6)
Placental abruption — no. (%) 11 (2.2) 11 (2.3) 0.94 (0.40–2.21)
Severe hypertension — no. (%) 200 (40.6) 134 (27.5) 1.80 (1.34–2.38)
Preeclampsia — no./total no. (%) 241/493 (48.9) 223/488 (45.7) 1.14 (0.88–1.47)
Defined only by new proteinuria¶ 148/493 (30.0) 132/488 (27.0) 1.08 (0.74–1.59)
At least one symptom of preeclampsia‖ 171/493 (34.7) 156/488 (32.0) 1.11 (0.84–1.46)
Abnormal laboratory test results
Platelet count <100×109/liter 21/493 (4.3) 8/488 (1.6) 2.63 (1.15–6.05)
Elevated AST or ALT level, with symptoms 21/492 (4.3) 9/488 (1.8) 2.33 (1.05–5.16)
Elevated LDH level, with symptoms 16/491 (3.3) 9/488 (1.8) 1.78 (0.77–4.11)
HELLP syndrome** 9/493 (1.8) 2/488 (0.4) 4.35 (0.93–20.35)
Serum creatinine level >2.3 mg/dl 0 1/488 (0.2)
*  The secondary outcome was serious maternal complications occurring up to 6 weeks post partum or until hospital 
discharge, whichever was later. There were no significant differences in other maternal outcomes between the groups 
except with respect to severe hypertension (blood pressure, ≥160 mm Hg systolic or ≥110 mm Hg diastolic; 
P<0.001). There were notable but not significant between‑group differences with respect to platelet count (P<0.05) 
and elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels with symptoms (P<0.05). To 
convert the value for serum creatinine to micromoles per liter, multiply by 88.4. HELLP denotes hemolysis, elevated 
liver‑enzyme levels, and a low platelet count; and LDH lactate dehydrogenase.
†  The mixed‑effects logistic‑regression model was adjusted for stratification factors (type of hypertension [preexisting or 
gestational] and center), the use of any antihypertensive therapy at randomization, previous blood pressure of 
160/110 mm Hg or higher during this pregnancy, gestational diabetes, and weeks of gestation at randomization.
‡  A woman could have more than one complication. No woman died or had any of the following complications: ec‑
lampsia, blindness, respiratory failure, hepatic dysfunction, hepatic hematoma or rupture, myocardial ischemia or in‑
farction, or the required use of inotropic agents.
§  Antepartum transfusion was received by one woman in the tight‑control group (she also received a postpartum trans‑
fusion). Postpartum transfusion was administered for anemia not otherwise specified (four women in the less‑tight‑
control group and four in the tight‑control group), postpartum hemorrhage (five women in the less‑tight‑control 
group and two in the tight‑control group), HELLP syndrome (three women in the less‑tight‑control group), operative 
blood loss (three women in the less‑tight‑control group), and placental abruption (one woman in the less‑tight‑con‑
trol group and two in the tight‑control group).
¶  Proteinuria was determined by the highest amount recorded by whichever method was used (i.e., ≥0.3 g of protein in 
a 24‑hour urine collection, a urinary protein:creatinine ratio of ≥263 [with protein measured in milligrams per day and 
creatinine in grams per day], or a urinary dipstick result of ≥2+).
‖  Examples of symptoms of preeclampsia are headache (persistent, new, or unusual), visual disturbances, chest pain, 
dyspnea, severe nausea or vomiting, and persistent right‑upper‑quadrant or epigastric abdominal pain.
**  The HELLP syndrome was defined as a platelet count less than 100×109 per liter and either elevated AST or ALT lev‑
els in association with symptoms or an elevated LDH level in association with symptoms.
Table 3. Secondary and Other Maternal Outcomes.*
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sonable adherence to the management algorithm 
(Fig. S2 in the Supplementary Appendix).
Discussion
This randomized trial showed that less-tight con-
trol of maternal hypertension in pregnancy as 
compared with tight control resulted in no sig-
nificant difference in the risk of adverse perina-
tal outcomes, as assessed by the rates of perina-
tal death or high-level neonatal care for more than 
48 hours (our primary outcome). On the basis of 
the 95% confidence interval around the risk es-
timate and an event rate of 30.4% in the tight-
control group, the results are compatible with 
no more than a 5.2 percentage-point decrease or 
6.6 percentage-point increase in the rate of the 
primary outcome with less-tight as compared 
with tight control.
Less-tight (vs. tight) control did not signifi-
cantly increase the risk of overall serious maternal 
complications (our secondary outcome), although 
our findings are compatible with anywhere from 
a 0.7 percentage-point decrease to a 4.0 percent-
age-point increase in the rate of this outcome. 
Less-tight control was associated with a higher 
risk of severe maternal hypertension than was 
tight control. Although less-tight control was also 
associated with a higher risk of a platelet count 
less than 100×109 per liter and elevated liver-
enzyme levels in association with symptoms, the 
P values for these associations did not reach the 
prespecified level of significance for “other out-
comes.”
Our trial is substantially larger than previous 
trials that have examined the effects of lower 
versus higher blood-pressure targets during 
pregnancy (with previous trials having randomly 
assigned women to antihypertensive therapy or 
placebo or no treatment).5 With respect to the 
mothers, our findings are consistent with a meta-
analysis of previous trials (29 trials involving 
3350 women) that showed that less-tight versus 
tight control increases the incidence of severe 
maternal hypertension (but not preeclampsia).5 
Severe hypertension is a risk factor for acute stroke 
during and outside of pregnancy.15,21 The rates of 
severe hypertension were higher in the current 
study than in some previous trials (in which the 
rate was approximately 20% in the placebo or 
no-therapy group),5 even though almost half the 
women in CHIPS performed blood-pressure moni-
toring at home. CHIPS may have identified women 
with true hypertension; the rates of severe hyper-
tension were consistent with those in trials that 
recruited women with hypertension early in the 
second trimester, when blood pressure during 
pregnancy is lowest.6,9
Meta-analyses of previous randomized, con-
trolled trials have suggested that lower blood 
pressure (achieved with the use of antihyperten-
sive therapy) versus higher blood pressure may 
result in lower birth weight and a heightened 
risk of small-for-gestational-age newborns.7,8 In 
contrast, another meta-analysis of randomized, 
Figure 2. Blood-Pressure Values among Women with 
Severe Hypertension.
Panel A shows the percentage of women with systolic 
blood pressure of 160 mm Hg or higher, and Panel B 
shows the percentage of women with diastolic blood 
pressure of 110 mm Hg or higher. I bars represent 
95% confidence intervals.
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controlled trials involving pregnant women 
showed that tight control with beta-blockers 
(including labetalol) was associated with fewer 
neonatal respiratory complications, but this was 
subject to potential publication bias.16 Our find-
ings of no significant between-group differences 
in the primary or other perinatal outcomes do 
not support these potential benefits or risks of 
less-tight versus tight control.
Before the start of the trial, the target differ-
ence in blood pressure was 5 mm Hg. We achieved 
mean differences of 5.8 mm Hg in systolic blood 
pressure and 4.6 mm Hg in diastolic blood pres-
sure, differences that were consistent with those 
achieved in trials involving nonpregnant partici-
pants in which lower versus “standard” targets 
were evaluated.22
A limitation of our trial was that we included 
women with either preexisting or gestational hy-
pertension, but results for the primary and sec-
ondary outcomes were similar for each hyperten-
sion type. Our primary and secondary outcomes 
included some causes of pregnancy loss (miscar-
riage and elective termination) and some inter-
ventions for high-level neonatal care that were not 
expected to be associated with maternal blood-
pressure control; however, these causes and inter-
ventions (including no ectopic pregnancies in ei-
ther group) were infrequent and were balanced 
between the groups. Although labetalol was 
considered to be the antihypertensive agent of 
choice in this study, it was used by only two 
thirds of the women who received antihyperten-
sive medication after randomization. We did not 
collect information on common adverse effects 
of antihypertensive medications, but few women 
had medication adjusted for reasons other than 
blood-pressure control. In a meta-analysis of ran-
domized, controlled trials of antihypertensive 
therapy in pregnancy, only 3.4% of women treated 
with antihypertensive agents changed drugs be-
cause of maternal side effects.5
In summary, we found no significant differ-
ences in the rates of major adverse perinatal out-
comes or overall serious maternal complications 
in association with less-tight versus tight control 
of blood pressure. However, less-tight control was 
associated with a higher rate of severe maternal 
hypertension.
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